Date	Headline
Jun 03, 2019	Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
Jun 03, 2019	Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
May 09, 2019	Provectus Appoints Bruce Horowitz as Chief Operating Officer
Apr 17, 2019	Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 25, 2019	Provectus Appoints Heather Raines, CPA as Chief Financial Officer

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
May 13, 2019	10-Q	Quarterly report	html pdf xbrl
May 09, 2019	10-K/A	Annual report (Amendment)	html pdf
Mar 07, 2019	10-K	Annual report	html pdf xbrl
Nov 08, 2018	10-Q	Quarterly report	html pdf xbrl
Aug 07, 2018	10-Q	Quarterly report	html pdf xbrl

Company Overview